Lagevrio (Molnupiravir) Approved for Mild-to-Moderate COVID-19 Treatment: A Game Changer?
The FDA has approved Lagevrio (molnupiravir) 200mg C for treating mild-to-moderate COVID-19 in high-risk adults. This antiviral works by stopping the virus from replicating, potentially reducing hospitalization and death. While promising, it's crucial to weigh the benefits against potential side effects like diarrhea, upset stomach, and dizziness. Also, be aware of severe reactions and seek emergency medical attention for signs of an allergic reaction like hives or rapid heartbeat.
I'm curious to hear from folks who've had experience with Lagevrio. What was your experience like? How did you handle the side effects? I'm aware this is new, but hopefully, someone has some input.
Are there any medical professionals here who can share more details on Lagevrio's efficacy and how it compares to other COVID-19 treatments? I'd love to hear your insights.
COVID19
Molnupiravir
Medicine
jean_hudson · 4/18/20261 min read
last active 4/18/2026
HOT